Cargando…

Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease

BACKGROUND: Monoclonal antibodies inhibiting tumour necrosis factor-α (TNFα) signalling pathway (anti-TNFα) have been widely used in Crohn’s disease (CD). However, treatment response varies among patients with CD and the clinical outcome is dependent on single nucleotide polymorphisms (SNP) in TNFα...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qasem, Ahmad, Ramesh, Seela, Naser, Saleh A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361334/ https://www.ncbi.nlm.nih.gov/pubmed/30815272 http://dx.doi.org/10.1136/bmjgast-2018-000246

Ejemplares similares

TNFα inhibitors exacerbate Mycobacterium paratuberculosis infection in tissue culture: a rationale for poor response of patients with Crohn’s disease to current approved therapy
por: Qasem, Ahmad, et al.
Publicado: (2018)

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
por: Schmitt, Heike, et al.
Publicado: (2019)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Inability to walk: a rare presentation of Crohn’s disease
por: Hoekstra, Elmer, et al.
Publicado: (2020)

Variables associated with progression of moderate-to-severe Crohn’s disease
por: Sacramento, Carolina da Silva Beda, et al.
Publicado: (2022)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

A novel unconventional T cell population enriched in Crohn’s disease
por: Rosati, Elisa, et al.
Publicado: (2022)

Creeping fat formation and interaction with intestinal disease in Crohn's disease
por: Yin, Yi, et al.
Publicado: (2022)

Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease
por: Salem, Mohammad, et al.
Publicado: (2015)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Perianal fistulizing Crohn's disease and overall risk of cancer: No red flag
por: McLellan, Paul, et al.
Publicado: (2023)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT‐TOPIC trial after 1‐year follow‐up
por: Lansdorp, Corine A., et al.
Publicado: (2022)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease
por: Schwerd, Tobias, et al.
Publicado: (2017)

Therapeutic Effect of Vitamin D Supplementation in a Pilot Study of Crohn's Patients
por: Yang, Linlin, et al.
Publicado: (2013)

Study of the Viral and Microbial Communities Associated With Crohn's Disease: A Metagenomic Approach
por: Pérez-Brocal, Vicente, et al.
Publicado: (2013)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
por: Fernandes, Samuel Raimundo, et al.
Publicado: (2022)

Understanding progression of strictures in ileal Crohn's disease—The importance of setting methodological standards
por: Tavares de Sousa, Helena, et al.
Publicado: (2022)

Editorial: Postoperative management of Crohn's disease: One size does not fit all
por: Domènech, Eugeni, et al.
Publicado: (2023)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Crohn's disease related strictures in cross‐sectional imaging: More than meets the eye?
por: Sleiman, Joseph, et al.
Publicado: (2022)

Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
por: Gaujoux, Renaud, et al.
Publicado: (2019)

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
por: Narula, Neeraj, et al.
Publicado: (2021)

Validation of stricture length, duration and obstructive symptoms as predictors for intervention in ileal stricturing Crohn's disease
por: El Ouali, Sara, et al.
Publicado: (2022)

Malignancy rates in Crohn's disease patients with perianal fistula: A German retrospective cohort study
por: Podmore, Bélène, et al.
Publicado: (2023)

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Developing in vitro expanded CD45RA(+) regulatory T cells as an adoptive cell therapy for Crohn's disease
por: Canavan, James B, et al.
Publicado: (2016)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
por: Ma, Christopher, et al.
Publicado: (2017)

Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010–2014
por: Akhuemonkhan, Eboselume, et al.
Publicado: (2017)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ed8hicneskb9rnfkm6u3b58cod